A commercial-stage rare disease company focused on cholestatic liver diseases and related disorders of bile acid biology, with a portfolio of marketed medicines and a pipeline built around IBAT inhibition and liver-targeted development.
A commercial-stage rare disease company focused on cholestatic liver diseases and related disorders of bile acid biology, with a portfolio of marketed medicines and a pipeline built around IBAT inhibition and liver-targeted development.
